CA3037059A1 - Compositions and methods for treating alzheimer's disease and parkinson's disease - Google Patents

Compositions and methods for treating alzheimer's disease and parkinson's disease Download PDF

Info

Publication number
CA3037059A1
CA3037059A1 CA3037059A CA3037059A CA3037059A1 CA 3037059 A1 CA3037059 A1 CA 3037059A1 CA 3037059 A CA3037059 A CA 3037059A CA 3037059 A CA3037059 A CA 3037059A CA 3037059 A1 CA3037059 A1 CA 3037059A1
Authority
CA
Canada
Prior art keywords
tablet
syn120
day
another embodiment
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3037059A
Other languages
English (en)
French (fr)
Inventor
Christopher G. Salentine
Thomas R. Malefyt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Inc
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of CA3037059A1 publication Critical patent/CA3037059A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3037059A 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease Abandoned CA3037059A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402357P 2016-09-30 2016-09-30
US62/402,357 2016-09-30
PCT/US2017/054473 WO2018064559A1 (en) 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease

Publications (1)

Publication Number Publication Date
CA3037059A1 true CA3037059A1 (en) 2018-04-05

Family

ID=61756894

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3037059A Abandoned CA3037059A1 (en) 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease

Country Status (10)

Country Link
US (3) US10314798B2 (enExample)
EP (1) EP3518914A4 (enExample)
JP (1) JP2019529502A (enExample)
AR (1) AR109760A1 (enExample)
AU (2) AU2017337053B2 (enExample)
CA (1) CA3037059A1 (enExample)
IL (1) IL265656A (enExample)
MX (2) MX387961B (enExample)
TW (1) TWI753952B (enExample)
WO (1) WO2018064559A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017337053B2 (en) 2016-09-30 2021-09-02 Biotie Therapies, Inc. Compositions and methods for treating alzheimer's disease and parkinson's disease
CN114901262A (zh) * 2019-11-04 2022-08-12 辛克鲁斯制药控股有限公司 X842的口服制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368083A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
SI1831159T1 (sl) * 2004-12-21 2010-04-30 Hoffmann La Roche Derivati tetralina in indana ter njune uporabe
EP2035370A2 (en) * 2006-06-20 2009-03-18 F. Hoffmann-Roche AG Tetralin and indane derivatives and uses thereof
FR2974102B1 (fr) * 2011-04-13 2014-08-22 Rhodia Operations Composition polyamide stabilisee
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
AU2017337053B2 (en) 2016-09-30 2021-09-02 Biotie Therapies, Inc. Compositions and methods for treating alzheimer's disease and parkinson's disease

Also Published As

Publication number Publication date
EP3518914A4 (en) 2020-06-10
MX2021014093A (es) 2021-12-10
US20190142771A1 (en) 2019-05-16
US20210177783A1 (en) 2021-06-17
IL265656A (en) 2019-05-30
JP2019529502A (ja) 2019-10-17
AU2021277698A1 (en) 2021-12-23
AR109760A1 (es) 2019-01-23
WO2018064559A1 (en) 2018-04-05
AU2017337053B2 (en) 2021-09-02
TW201813638A (zh) 2018-04-16
MX387961B (es) 2025-03-19
US10314798B2 (en) 2019-06-11
AU2017337053A1 (en) 2019-04-04
US10973784B2 (en) 2021-04-13
TWI753952B (zh) 2022-02-01
EP3518914A1 (en) 2019-08-07
MX2019003720A (es) 2019-09-19
US20180092868A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
JP4084309B2 (ja) 単一の結晶形を含有する固形製剤
KR101682963B1 (ko) 4,5-에폭시모르피난 유도체를 함유하는 안정한 정제
EP3501506B1 (en) Pharmaceutical tablet composition comprising brexpiprazole
KR20100015582A (ko) 4,5-에폭시모르피난 유도체를 함유하는 안정한 고형 제제
CN112739334B (zh) 结晶丙二酸肾上腺素盐
EP3749286B1 (en) A pharmaceutical composition comprising metamizole, drotaverine, and caffeine
IL293879A (en) Compositions of bile acids and phenylbutyrate compounds
AU2021277698A1 (en) Compositions and methods for treating Alzheimer&#39;s disease and Parkinson&#39;s disease
JP2025169294A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
WO2013082706A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
WO2010041277A2 (en) Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates
WO2008071966A2 (en) Pharmaceutical composition of zolpidem
KR20160014619A (ko) 공-결정체 형태로 아고멜라틴을 포함하는 아고멜라틴 제형
JP7336528B2 (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
EP4233849A1 (en) Pharmaceutical composition comprising pomalidomide
EA033685B1 (ru) Фармацевтические лекарственные формы
JP2011153135A (ja) タルチレリン製剤およびタルチレリン製剤の溶出性維持方法
RU2410097C2 (ru) Лекарственная форма триметазидина модифицированного высвобождения и способ ее получения (варианты)
HK40072206A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
EP1928863A2 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
KR20250034266A (ko) 설트랄린 또는 이의 염을 포함하는 약학적 조성물
HK40045152A (en) Crystalline epinephrine malonate salt
HK1155364A (en) Eprosartan compositions
HU230983B1 (hu) Módosított hatóanyag-leadású gyógyszerkészítmény

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240110